Global cost of cancer projected to exceed $25 Trillion by 2050

Cost of cancer by 2050

Share This Post

Feb 2023: According to data published in JAMA Oncology, the global economic cost of cancer is projected to reach $25,2 trillion in international dollars (INT) between 2020 and 2050.

North America is projected to have the highest cost, and China is projected to have the highest cost per capita. The cancers of the trachea, bronchus, and lung are anticipated to incur the highest costs.

Researchers used a macroeconomic model to make these forecasts. Between 2020 and 2050, they projected the cost of 29 cancers in 204 countries and territories.

The United States ($5,300 billion), China ($6,100 billion), and India ($1,400 billion) will bear the largest economic costs.

Bulgaria (1.42%), Monaco (1.33%), and Montenegro (1.0%) are the countries with the highest projected economic costs as a percentage of gross domestic product. The projected economic cost per capita is greatest in Monaco ($85,230), Ireland ($54,009), and Bermuda ($20,732)

North America is projected to have the highest economic burden from cancer as a proportion of gross domestic product, equivalent to a 0.83 percent annual tax. Europe and Central Asia (0.63%), East Asia and the Pacific (0.59%), and Sub-Saharan Africa (0.24%) follow.

By cancer type, the highest economic cost is projected for:

 

The researchers noted that these cancers account for half of the global economic cost of cancer.

The researchers wrote, “The macroeconomic cost of cancer was found to be substantial and heterogeneously distributed across cancer types, countries, and world regions.” The findings indicate that global efforts to reduce the prevalence of cancer are warranted.

A related editorial highlighted the study’s limitations, including the absence of data for 60 countries, or 7.3% of the total population.

Disclosures: The study authors reported having no conflicts of interest. The editorial author declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original references for a full list of disclosures.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Adagrasib with cetuximab has received accelerated approval by FDA for KRAS G12C-mutated colorectal cancer
Colon cancer

Adagrasib with cetuximab has received accelerated approval by FDA for KRAS G12C-mutated colorectal cancer

The FDA has granted accelerated approval to Adagrasib combined with Cetuximab for treating KRAS G12C-mutated colorectal cancer. This approval is based on promising clinical trial results showing enhanced efficacy of the drug duo. Adagrasib, a KRAS inhibitor, and Cetuximab, an EGFR inhibitor, together target the cancer more effectively, offering new hope for patients with this specific genetic mutation, aiming to improve survival rates and treatment outcomes.

Pembrolizumab with chemotherapy is approved by the USFDA for primary advanced or recurrent endometrial carcinoma
Endometrial cancer

Pembrolizumab with chemotherapy is approved by the USFDA for primary advanced or recurrent endometrial carcinoma

The USFDA has approved Pembrolizumab combined with chemotherapy for treating primary advanced or recurrent endometrial carcinoma. This approval is based on clinical trial data showing significant improvements in patient outcomes. Pembrolizumab, an immune checkpoint inhibitor, works by enhancing the body’s immune response against cancer cells. This combination therapy offers a new and promising treatment option for patients facing this challenging and often aggressive cancer.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy